ARCT (Arcturus Therapeutics Holdings Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ARCT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-15 | Moncef Slaoui | Director | A | — | — |
| 2026-06-15 | PETER C FARRELL | Director | A | — | — |
| 2026-06-15 | John Markels | Director | A | — | — |
| 2026-06-15 | Jing L. Marantz | Director | A | — | — |
| 2026-06-15 | EDWARD W HOLMES | Director | A | — | — |
| 2026-06-15 | JAMES F BARLOW | Director | A | — | — |
| 2026-06-15 | Magda Marquet | Director | A | — | — |
| 2026-05-07 | DENNIS MULROY | Chief Financial Officer | A | — | — |
| 2025-12-19 | Joseph E Payne | President and CEO | A | — | — |
| 2025-12-19 | Lance Kurata | Chief Legal Officer | A | — | — |
| 2025-12-19 | Joseph Roberts | Controller | A | — | — |
| 2025-12-19 | Pad Chivukula | Chief Scientific Officer & COO | A | — | — |
| 2025-08-20 | ANDY SASSINE | Chief Financial Officer | Buy | — | — |
| 2025-08-19 | ANDY SASSINE | Chief Financial Officer | Buy | — | — |
| 2025-06-11 | John Markels | Director | A | — | — |
| 2025-06-11 | PETER C FARRELL | Director | A | — | — |
| 2025-06-11 | Magda Marquet | Director | A | — | — |
| 2025-06-11 | Jing L. Marantz | Director | A | — | — |
| 2025-06-11 | JAMES F BARLOW | Director | A | — | — |
| 2025-06-11 | Moncef Slaoui | Director | A | — | — |
| 2025-06-11 | EDWARD W HOLMES | Director | A | — | — |
| 2024-12-18 | Lance Kurata | Chief Legal Officer | A | — | — |
| 2024-12-18 | Joseph E Payne | President and CEO | A | — | — |
| 2024-12-18 | Pad Chivukula | Chief Scientific Officer & COO | A | — | — |
| 2024-12-18 | ANDY SASSINE | Chief Financial Officer | A | — | — |
| 2024-10-16 | Pad Chivukula | Chief Scientific Officer & COO | Sell | — | — |
| 2024-06-21 | Moncef Slaoui | Director | A | — | — |
| 2024-06-18 | Jing L. Marantz | Director | M | — | — |
| 2024-06-18 | PETER C FARRELL | Director | M | — | — |
| 2024-06-18 | EDWARD W HOLMES | Director | M | — | — |
| 2024-06-18 | Magda Marquet | Director | M | — | — |
| 2024-06-18 | JAMES F BARLOW | Director | M | — | — |
| 2024-06-18 | John Markels | Director | M | — | — |
| 2024-06-14 | ANDY SASSINE | Chief Financial Officer | Sell | — | — |
| 2024-06-07 | Pad Chivukula | Chief Scientific Officer & COO | Sell | — | — |
| 2024-06-04 | Pad Chivukula | Chief Scientific Officer & COO | Sell | — | — |
| 2024-03-27 | Pad Chivukula | Chief Scientific Officer & COO | Sell | — | — |
| 2024-03-21 | Pad Chivukula | Chief Scientific Officer & COO | Sell | — | — |
| 2023-12-19 | Pad Chivukula | Chief Scientific Officer & COO | A | — | — |
| 2023-12-19 | ANDY SASSINE | Chief Financial Officer | A | — | — |
| 2023-12-19 | Lance Kurata | Chief Legal Officer | A | — | — |
| 2023-12-19 | Joseph E Payne | President and CEO | A | — | — |
| 2023-12-19 | Keith C Kummerfeld | See Remarks | A | — | — |
| 2023-11-03 | Pad Chivukula | Chief Scientific Officer & COO | Sell | — | — |
| 2023-10-04 | Pad Chivukula | Chief Scientific Officer & COO | Sell | — | — |
| 2023-09-05 | Pad Chivukula | Chief Scientific Officer & COO | Sell | — | — |
| 2023-08-17 | ANDY SASSINE | Chief Financial Officer | A | — | — |
| 2023-08-03 | Magda Marquet | Director | A | — | — |
| 2023-08-03 | Pad Chivukula | Chief Scientific Officer & COO | Sell | — | — |
| 2023-08-03 | John Markels | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 1,480,097 | — |
| — | Director | 1,400,000 | — |
| — | Chief Scientific Officer & COO | 435,334 | — |
| — | Chief Financial Officer | 221,764 | — |
| — | Director | 98,696 | — |
| — | Director | 28,073 | — |
| — | Director | 13,131 | — |
| — | Director | 3,131 | — |
| — | Director | 3,131 | — |
| — | Director | 3,131 | — |
| — | See Remarks | 950 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ARCT quote page; the site-wide leaderboard is on the insider transactions hub.